| Group-A: AZT and D4T n = 55 | ||
---|---|---|---|
HIVDR | High (%) | Intermediate (%) | Susceptible (%) |
3TC | 45 (81.8%) | 0 (0.0%) | 10 (18.2%) |
ABC | 11 (20.0%) | 19 (34.5%) | 25 (45.5%) |
AZT | 23 (41.8%) | 8 (14.6%) | 24 (43.6%) |
D4T | 23 (41.8%) | 7 (12.7%) | 25 (45.5%) |
DDI | 14 (25.4%) | 11 (20.0%) | 30 (54.6%) |
FTC | 45 (81.8%) | 0 (0.0%) | 10 (18.2%) |
TDF | 3 (5.5%) | 13 (23.6%) | 39 (70.9%) |
 | Group-B: TDF + D4T or AZT n = 22 | ||
---|---|---|---|
HIVDR | High (%) | Intermediate (%) | Susceptible (%) |
3TC | 19 (86.4%) | 0 (0.0%) | 3 (13.6%) |
ABC | 10 (45.5%) | 6 (27.3%) | 6 (27.3%) |
AZT | 3 (13.6%) | 5 (22.7%) | 14 (63.6%) |
D4T | 4 (18.2%) | 9 (40.9%) | 9 (40.9%) |
DDI | 10 (45.5%) | 2 (9.1%) | 5 (45.5%) |
FTC | 19 (86.4%) | 0 (0.0%) | 3 (13.6%) |
TDF | 6 (27.3%) | 1 (4.5%) | 15 (68.2%) |
 | Group-C: D4T (i.e. Triomune) n = 24 | ||
---|---|---|---|
HIVDR | High (%) | Intermediate (%) | Susceptible (%) |
3TC | 20 (83.3%) | 0 (0.0%) | 4 (16.7%) |
ABC | 7 (29.2%) | 8 (33.3%) | 9 (37.5%) |
AZT | 10 (41.7%) | 5 (20.8%) | 9 (37.5%) |
D4T | 10 (41.6%) | 5 (20.8%) | 9 (37.5%) |
DDI | 8 (33.3%) | 4 (16.7%) | 12 (50.0%) |
FTC | 20 (83.3%) | 0 (0.0%) | 4 (16.7%) |
TDF | 2 (8.3%) | 2 (8.3%) | 20 (83.3%) |